금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Nasdaq Opens Lower, Warsh Dodges Questions on July Rate Decision
U.S. stocks were in the red, with the Nasdaq composite retreating the most after U.S. stocks closed ...
United States ISM Manufacturing New Orders Index fell from previous 56.8 to 56 in June
United States ISM Manufacturing New Orders Index fell from previous 56.8 to 56 in June...
United States ISM Manufacturing PMI came in at 53.3 below forecasts (54) in June
United States ISM Manufacturing PMI came in at 53.3 below forecasts (54) in June...
Global policy uncertainty hits multi-year high, Goldman Sachs says
Groupe Dynamite GAAP EPS of C$0.45, revenue of C$310.58M
Pacer’s Dividend Multiplier ETF Pays 400% of the S&P 500’s Dividend, With a Catch Most Investors Don’t Notice
Income-based investors, such as retirees, often avoid high growth investments for (2) reasons: Capital risk due to market volatility Lack of income production The S&P 500 is a perfect example of this. ...
This Vanguard ETF Is Quietly Outpacing the S&P 500 in 2026 and Costs Just 0.04 Percent
The Vanguard Growth ETF (NYSEARCA:VUG) trades near $86 after a brutal five-day stretch that lopped 4.5% off the price. Year to date, VUG is up 6.2%, currently trailing the S&P 500’s 8.4% gain as megac ...
Nebius Soars 124% in 3 Months: Should You Buy, Hold, or Fold?
NBIS has surged 123.6% in three months as AI infrastructure, revenue growth and capacity expansion fuel momentum, but can it sustain the run?
VMI Stock Rallies 32% in 3 Months: What's Driving the Upside?
Valmont Industries' rally is backed by Infrastructure margin gains, utility demand, backlog growth and raised fiscal 2026 guidance.
SpaceX IPO: What Your $5,000 Investment Could Be Worth
The company's valuation prices in lofty growth expectations.
This Global ETF Is Beating the S&P 500 in 2026 -- but There's 1 ETF That I Like Better
Diversification might be a better long-term bet than dividends.
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3% gain. This might have investors contemplat ...
Hairy stuff: e.l.f. Beauty looks to disrupt a new category
Outlook gains as wet AMD therapy reconsidered for FDA review
Software stocks lose their aura on agentic AI disruptive threat